Trial Profile

A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions

Most Recent Events

14 Aug 2024 Planned End Date changed from 31 Jul 2024 to 13 Aug 2025.
14 Aug 2024 Planned End Date changed from 31 Jul 2024 to 13 Aug 2025.
11 Aug 2023 The procedures of MRI, CT, ECG, bone marrow Biopsy and bio-specimen collection have been added to the treatments section.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com